Scopolamine (hyoscine) for preventing and treating motion sickness

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Spinks, A B ^b   Wasiak, Jason ^a   Villanueva, E V ^b   Bernath, V ^b  

^a ALFRED HOSPITAL   (Australia)

^b NONE

Author keywords

Adult; Child; Motion sickness *drug therapy; prevention control ; Muscarinic antagonists adverse effects; *therapeutic use ; Randomized controlled trials as topic; Scopolamine adverse effects; *therapeutic use ; Treatment outcome

Indexed keywords

ANTIHISTAMINIC AGENT; CALCIUM ANTAGONIST; CINNARIZINE; CYCLIZINE; DIMENHYDRINATE; EPHEDRINE; LORAZEPAM; MECLOZINE; METHYLSCOPOLAMINE; PLACEBO; PROMETHAZINE; SCOPADERM; SCOPOLAMINE; SCOPOLAMINE BROMIDE;

BLURRED VISION; CINAHL; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; COLD SWEAT; DATA EXTRACTION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; EMBASE; FATIGUE; HEADACHE; HUMAN; HYPERSALIVATION; HYPERVENTILATION; MEDICAL LITERATURE; MEDLINE; MOTION SICKNESS; NAUSEA; OUTCOME ASSESSMENT; PALLOR; PUBLICATION; REVIEW; SYMPTOM; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

EID: 42249090480     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002851.pub3     Document Type: Review

References (49)

1. Attias 1987 {published data only} Attias J, Gordon C, Ribak J, Binah O, Rolnick A. Efficacy of transdermal scoplamine against seasickness: a 3-day study at sea. Aviation, Space and Environmental Medicine 1987;58:60-2.
2. Becker 1984 {published data only} Becker G, Goossens H, Seemann K, Souchon F, Weitz Th. Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy [Kinetoseprophylaxe mit TTS-Scopolamin. Une randomisierte, vergleichende Doppelblinstudie bei der Bundesmarine]. Deutsche Medizinische Wochenschrift 1984;109:1881- 5.
3. Brand 1968 {published data only} Brand JJ, Colquhoun WP, Perry WLM. Side-effects of 1-hyoscine and cyclizine studies by objective tests. Aerospace Medicine 1968;39:999-1002.
4. Dornhoffer 2004 {published data only} Dornhoffer J, Chelonis JJ, Blake D. Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic counter-measures for space motion sickness. Otology and Neurotology 2004;25:740-745.
5. Hargreaves 1982 {published data only} Hargreaves J. The prophylaxis of seasickness. A comparison of cinnarizine with hyoscine. New Zealand Medical Journal 1982;226:160-1.
6. How 1988 {published data only} How J, Lee PS, Seet LC, Tan PK. The Republic of Singapore Navy's Scopoderm TTS Study: results after 2,200 man-days at sea. Aviation, Space and Environmental Medicine 1988;59:646-50.
7. Laitinen 1981 {published data only} Laitinen LA, Tokola O, Gothoni G, Vapaatalo H. Scopolamine alone or combined with ephedrine in seasickness: a double blind, placebo-controlled study. Aviation, Space and Environmental Medicine 1981;52:6-10.
8. Nuotto 1983 {published data only} Nuotto E. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. European Journal of Clinical Pharmacology 1983;24:603-9.
9. Offenloch 1986 {published data only} Offenloch K. Comparative in-flight study of a scopolamine containing membrane plaster versus dimenhydrinate under defined acceleration conditions [Vergleichende Inflight-Untersuchung eines Scopolamin-haltigen Membranpflasters versus Dimenhydrinat unter definierten Beschleunigungsreizen]. Aezneimittelforschung 1986;36:1401-6.
10. Pingree 1994 {published data only} Pingree BJW, Pethybridge RJ. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness. Aviation, Space and Environmental Medicine 1994;65:597-605.
11. Price 1981 {published data only} Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G. Transdermal scopolamine in the prevention of motion sickness at sea. Clinical Pharmacology and Therapeutics 1981;29:414-9.
12. Tokola 1984 {published data only} Tokola O, Laitinen LA, Aho J, Gothoni G, Vapaatalo H. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations. Aviation, Space, and Environmental Medicine 1984;55:636-41.
13. Uijdehaage 1993 {published data only} Uijdehaage SHJ, Stern RM, Koch KL. Effects of scopolamine on autonomic profiles underlying motion sicknes susceptibility. Aviation, Space and Environmental Medicine 1993;64:1-8.
14. van Marion 1985 {published data only} van Marion WF, Bongaerts MCM, Christiaanse JC, Hofkamp HG, van Ouwerkerk W. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. Clinical Pharmacology and Therapeutics 1985;38:301-305.
15. Aizikov 1985 Aizikov GS. Effect of experimental motion sickness on prostrotatory nystagmus and the illusion of the counter rotation. Kosmicheskaia Biologiia i Aviakosmicheskaia Meditsina 1985;19:89-91.
16. Bodo 1982 Bodo D, Kotovskaia AR, Galle RR, Gavrilova LN, Gusakova GA. Effectiveness of the preparation Gavinton in preventing motion sickness. Kosmicheskaia Biologiia i Aviakosmicheskaia Meditsina 1982;16:49-51.
17. Brand 1967 Brand JJ, Colquhoun WP, Gould AH, Perry WLM. Hyoscine and cyclizine as motion sickness remedies. British Journal of Pharmacology and Chemotherapy 1967;30:463-469.
18. Brand 1969 Brand JJ. A comparison of the effects of hyoscine and amylobarbitone sodium on measurements of post-rotational turning sensation and nystagmus. Acta oto-laryngologica 1969;68:427-434.
19. Cipriani 1987 Cipriani G, Perazzetti F, Di Luzio Paparetti U, Cipriani GC. A double blind study using transdermal scopolamine for peripheral vestibular vertigo [Studio clinico in doppio cieco sull'utilizzazione della scopolamina per via transdermica nella vertigine vestibolare periferica]. Valsalva 1987;63:58-62.
20. Cirillo 1986 Cirillo B, Sabato F, Vigliano R. Seasickness prevention and therapy [La naupatia: prevenzione e terapia]. Annalis di Medicina Navale 1986;91:161-70.
21. Estrada 2007 Estrada A, LeDuc PA, Curry IP, Phelps SE, Fuller DR. Airsickness prevention in helicopter passengers. Aviation Space and Environmental Medicine 2007;78(4):408-13.
22. Galle 1988 Galle RR. Evaluation of the effectiveness of drugs for prevention of motion sickness. Kosmicheskaia Biologiia i Aviakosmicheskaia Meditsina 1988;22:90-4.
23. Glaznikov 1992 Glaznikov LA, Yanov Yu K, Butko Yu D, Shutov EB. On pharmacoprophylaxis of motion disease syndrome occurring. Zhurnal Ushnykh, Nosovykh i Gorlovykh Boleznei 1992;52:31-7.
24. Gordon 2001 Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A. The effects of dimenhydrinate, cinnarazine and transdermal scopolamine on performance. Journal of Psychopharmacology 2001;15:167-72.
25. Gowans 2000 *Gowans J, Matheson A, Darlington CL, Smith PF. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans. Journal of Vestibular Research 2000;10:87-92.
26. Hordinsky 1982 Hordinsky JR, Schwartz E, Beier J, Martin J, Aust G. Relative efficacy of the proposed space shuttle antimotion sickness medications. Acta Astronautica 1982;9:375-383.
27. Howland 2006 Howland J. Effects of Transdermal Scopolamine on Occupational Performance. www.clinicaltrials.gov 2006.
28. Ilyina 1986 Ilyina SL, Sabaev VV, Shashkov VS, Karsanova SK. The effect of pharmacological agents preventing the 'motion sickness syndrome' on the cardiovascular system in modelling the early period of adaption to weightlessness. Farmakologiya i Toksikologiya 1986;49:90-5.
29. Klocker 2001 *Klocker N, Hanschke W, Toussaint S, Verse T. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. European Journal of Pharmaceutical Sciences 2001;13:227-32.
30. Norfleet 1992 Norfleet WT, Degioanni JJ, Calkins DS, Reschke MF, Bungo MW, Kutyna FA, Homick JL. Treatment of motion sickness in parabolic flight with buccal scopolamine. Aviation, Space and Environmental Medicine 1992;63:46-51.
31. Pyyko 1984 *Pyykko I, Padoan S, Schalen L, Lyttkens L, Magnusson M, Henriksson NG. The effects of TTS-Scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviation, Space and Environmental Medicine 1985;56:777-82.
32. Pyykko I, Schalen L, Jantti V. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness. Acta Otolaryngol (Stockholm) 1985;99:588-96.
33. Pyykko I, Schalen L, Jantti V, Magnusson M. A reduction of vestibulo-visual integration during transdermally administered scopolamine and dimenhydrinate. Acta Otolaryngolica (Stockholm) 1984;406(Suppl): 167-73.
34. Pyykko I, Schalen L, Matsuoka I. Transdermally administered scopolamine vs. dimenhydrinate. II. Effect on the different types of nystagmus. Acta Otolaryngol (Stockholm) 1985;99:597-604.
35. Sabato 1987 Sabato F, Vigliano R, Cirillo V. Treatment of motion sickness with scopolamine by the transdermal route [Trattamento della naupatia mediante scopolamina somministrata per via transdermica]. Annali di Medicina Navale 1987;92:111-6.
36. Vigliano 1986 Vigliano R, Cirillo V, Sabato F, Cattoni M. Seasickness prevention using scopolamine (TCS mode), and placebo [Trattamento preventivo della naupatia con scopolamina per via transcutanea (TTS), dimenidrinato e placebo]. Annali di Medicina Navale 1986;91:153- 60.
37. Vigliano 1987 Vigliano R, Cirillo V, Sabato F, Cattoni M. Prevention of sea sickness with transdermal scopolamine, dimenhydrinate and a placebo. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche 1987;146:391-4.
38. Wang 1990 Wang E. Transdermal therapeutic system of (TTS-S) in the prevention of sea sickness and its mechanism of action. Zhonghua Er Bi Yan Hou Ke Za Zhi 1990;25:299-302, 319.
39. Wolf 1987 Wolf M, Kronenberg J, Leventon G. Comparison of transdermal scopolamine and dimenhydrinate in acute vestibular disease. Harefua 1987;113:65-66.
40. Antuano 1989 Antuano MJ, Hernandez JM. Incidence of air sickness among military parachutists. Aviation, Space and Environmental Medicine 1989;60:792-7.
41. Del Mar 2001 Del Mar CB, Silagy CA, Glasziou PP, Weller D, Spinks A, Bernath V, Anderson JN, Hilton DJ, Sanders SL. Feasibility of an evidence-based literature search service for general practitioners. The Medical Journal of Australia 2001;175:134-7.
42. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327:556-560.
43. Lawther 1988 Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviation, Space and Environmental Medicine 1988;59:399-406.
44. Oman 1990 Oman CM. Motion sickness: a synthesis and evaluation of the sensory conflict theory. Canadian Journal of Physiology and Pharmacology 1990;68:294-303.
45. Reason 1970 Reason JT. Motion sickness: a special case of sensory rearrangement. Advancement of Science 1970;26:386-93.
46. Reason 1975 Reason JT, Brand JJ. Motion Sickness. London: Academic Press, 1975.
47. Schultz 1995 Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
48. Ungs 1988 Ungs TJ. Simulator induced syndrome in Coast Guard aviators. Aviation, Space and Environmental Medicine 1988;59:267- 72.
49. Yardley 1992 Yardley L. Motion sickness and perception: a reappraisal of the sensory conflict approach. British Journal of Psychology 1992;83(4):449-71.